GLP-3 Tracker
Track GLP-3 (GLP3-RT) — the retatrutide triple agonist
GLP-3 — or "GLP3-RT" — is the community name for retatrutide (nicknamed "Reta"), the GLP-1/GIP/glucagon triple agonist. It is not an official drug class; the "3" just reflects three receptors. Shotlee is the free app to track your GLP-3 protocol: doses, weight, and side effects. It remains investigational and not FDA approved.
GLP-3 is retatrutide — here is what that means
When people say GLP-3, GLP3, or GLP3-RT, they mean retatrutide (Eli Lilly’s LY3437943). The nickname comes from it being a "triple" agonist — hitting GLP-1, GIP, and glucagon receptors — one step past the GLP-1/GIP dual drugs like tirzepatide. There is no official "GLP-3 receptor."
The extra glucagon mechanism adds energy expenditure and liver-fat reduction. In Phase 3 TRIUMPH-4, the highest dose averaged 28.7% weight loss at 68 weeks — the deepest reported in an obesity trial so far.
GLP-3 (Retatrutide) Key Facts
What to Track in Shotlee
Log your GLP-3 protocol and build clean baseline data.
Protocol FAQs
GLP-3 (also GLP3-RT) is the community nickname for retatrutide, the GLP-1/GIP/glucagon "triple" agonist. It is not an official receptor or class — the "3" reflects three receptors, one more than GLP-1/GIP duals like tirzepatide.
Yes. GLP-3, GLP3, and GLP3-RT all refer to retatrutide (LY3437943). The "RT" stands for retatrutide.
GLP-1 drugs activate one receptor; "GLP-3"/retatrutide activates three (GLP-1, GIP, glucagon). The added glucagon mechanism raises energy expenditure and reduces liver fat, which is linked to its deeper weight loss.
No. Retatrutide ("GLP-3") is investigational and only available in clinical trials. Grey-market GLP3-RT is unregulated research material.
Open Shotlee, log each injection (date, dose, site), and track weight, side effects, and labs alongside. It is free, and reminders keep you consistent.
Track GLP-3 (Retatrutide) in Shotlee
Free dose logging, weight trends, and side effect tracking — build your baseline now.